| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Endocrine Care |
Division of Endocrinology, Metabolism, Nutrition, and Internal Medicine (D.E., Y.C.K., W.F.Y.), Department of Neurosurgery (M.J.E.), and Department of Surgery (G.B.T., C.S.G., J.A.v.H.), Mayo Clinic, and Mayo Foundation, Rochester, Minnesota 55905
Address all correspondence and requests for reprints to: William F. Young, Jr., M.D., Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905. E-mail: Young.William{at}mayo.edu
Abstract
Paragangliomas are rare tumors that arise from extraadrenal chromaffin cells. We examined the clinical characteristics, location, treatment, and outcome of 236 patients (141 females, 60%) with 297 benign paragangliomas evaluated at the Mayo Clinic during 1978–1998. The mean age (±SD) at diagnosis was 47 ± 16 yr. Of the 297 paragangliomas, 205 were in the head and neck region, and 92 were below the neck. Paragangliomas were discovered and diagnosed incidentally on imaging studies in 9% of patients. Biochemical screening was performed in 128 patients; 40 patients (17% of the total and 31% of those screened) had hyperfunctional tumors. Of the 40 patients with tumoral catecholamine excess, 38 had documented hypertension. In patients identified with catecholamine-secreting paragangliomas, the sensitivities achieved by measurements in the 24-h urine collection were 74% for total metanephrines, 84% for norepinephrine, 18% for dopamine, and 14% for epinephrine. Multiple imaging modalities were used for tumor localization. The false negative rates were 0% for magnetic resonance imaging, 5.8% for computed tomography, 3.4% for angiography, 10.7% for ultrasonography, and 39% for radioactive iodine-labeled metaiodobenzylguanidine scintigraphy. Of 192 patients (81.4%) with follow-up data (mean, 43.9 months; range, 0.5–240), operative cure was achieved in 133 (69%). Of the 59 patients without cure, 23 had persistent disease, 5 had recurrent disease, 16 had multiple persistent synchronous tumors, and 15 subsequently developed metachronous tumors. In conclusion, most paragangliomas are nonhypersecretory and located in the head and neck region. Magnetic resonance imaging was associated with the lowest false negative rate, and metaiodobenzylguanidine was the least sensitive imaging study. A significant proportion of patients (31%) has persistent or recurrent disease, and long-term follow-up is important.
This article has been cited by other articles:
 |
|
 |
|
  A. Karagiannis, D. P Mikhailidis, V. G Athyros, and F. Harsoulis Pheochromocytoma: an update on genetics and management Endocr. Relat. Cancer, December 1, 2007; 14(4): 935 - 956. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. ZAPANTI and I. ILIAS Pheochromocytoma: Physiopathologic Implications and Diagnostic Evaluation Ann. N.Y. Acad. Sci., November 1, 2006; 1088(1): 346 - 360. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. F YOUNG JR Paragangliomas: clinical overview. Ann. N.Y. Acad. Sci., August 1, 2006; 1073: 21 - 29. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. AHLMAN Malignant pheochromocytoma: state of the field with future projections. Ann. N.Y. Acad. Sci., August 1, 2006; 1073: 449 - 464. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Y. Lee, Y.-W. Oh, H. J. Noh, Y. J. Lee, H.-S. Yong, E.-Y. Kang, K. A. Kim, and N. J. Lee Extraadrenal paragangliomas of the body: imaging features. Am. J. Roentgenol., August 1, 2006; 187(2): 492 - 504. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. F. Young Jr and A. L. Abboud Paraganglioma--all in the family. J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 790 - 792. [Full Text] [PDF]
|
|
|
|
|
|
G. Eisenhofer, D. S. Goldstein, P. Sullivan, G. Csako, F. M. Brouwers, E. W. Lai, K. T. Adams, and K. Pacak Biochemical and Clinical Manifestations of Dopamine-Producing Paragangliomas: Utility of Plasma Methoxytyramine J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2068 - 2075. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. G. Abud, C. Mounayer, G. Benndorf, M. Piotin, L. Spelle, and J. Moret Intratumoral Injection of Cyanoacrylate Glue in Head and Neck Paragangliomas AJNR Am. J. Neuroradiol., October 1, 2004; 25(9): 1457 - 1462. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Kaltsas, G. M. Besser, and A. B. Grossman The Diagnosis and Medical Management of Advanced Neuroendocrine Tumors Endocr. Rev., June 1, 2004; 25(3): 458 - 511. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. D. Garovic, M. C. Hogan, S. K. R. Kanakiriya, C. S. Grant, and W. F. Young Jr Labile hypertension, increased metanephrines and imaging misadventures Nephrol. Dial. Transplant., April 1, 2004; 19(4): 1004 - 1006. [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. Saurborn, J. B. Kruskal, I. E. Stillman, and S. Parangi Best Cases from the AFIP: Paraganglioma of the Organs of Zuckerkandl RadioGraphics, September 1, 2003; 23(5): 1279 - 1286. [Full Text] [PDF]
|
|
|
|
|
|
C. A. KOCH, A. O. VORTMEYER, Z. ZHUANG, F. M. BROUWERS, and K. PACAK New Insights into the Genetics of Familial Chromaffin Cell Tumors Ann. N.Y. Acad. Sci., September 1, 2002; 970(1): 11 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Young, B. E. Baysal, A. Deb, and W. F. Young Jr. Familial Malignant Catecholamine-Secreting Paraganglioma with Prolonged Survival Associated with Mutation in the Succinate Dehydrogenase B Gene J. Clin. Endocrinol. Metab., September 1, 2002; 87(9): 4101 - 4105. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B E Baysal Hereditary paraganglioma targets diverse paraganglia J. Med. Genet., September 1, 2002; 39(9): 617 - 622. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. G. Dluhy Pheochromocytoma -- Death of an Axiom N. Engl. J. Med., May 9, 2002; 346(19): 1486 - 1488. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
